Christine Anne Miller, Melinta Therapeutics CEO

Melin­ta se­cures $142M BAR­DA deal to tar­get pe­di­atric and 'bio­threat' in­di­ca­tions for an­tibi­otics

Melin­ta Ther­a­peu­tics se­cured a BAR­DA deal worth near­ly $142 mil­lion to make two cur­rent­ly ap­proved an­tibi­otics avail­able for chil­dren.

The deal comes rough­ly three years af­ter Deer­field Man­age­ment ac­quired the an­tibi­otics com­pa­ny and tapped CEO Chris­tine Ann Miller to re­struc­ture it. De­spite the ris­ing threat of an­timi­cro­bial re­sis­tance (AMR), Big Phar­ma has large­ly re­treat­ed from the high-risk field where many an­tibi­otics fail in de­vel­op­ment while oth­ers lan­guish due to a lack of avail­able fund­ing. The ones that do get ap­proved are used spar­ing­ly to pre­serve ef­fi­ca­cy and slow fur­ther re­sis­tance.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.